Extended Data Fig. 5: Comparison of T-ALL sensitivity to three LCK inhibitors.
a,b, A total of 11 cases were selected to represent dasatinib-sensitive vs resistant T-ALL (N = 7 and 4 in Panels a and b, respectively) and were xenografted in NSG mice to develop PDX. Mice were sacrificed once leukemia burden reached predefined endpoint, and human leukemia cells were harvested and subjected to drug sensitivity profiling ex vivo. Cells were incubated with increasing concentrations of each LCK inhibitor for 96 hours and cell viability was determined by flow cytometry as described in Methods. c, Dose-dependent cell death was determined for two drugs in 8 T-ALL cell lines. For both drugs, HSB-2, (harbors TCR-LCK fusion) and KOPT-K1 (harbors TCR-LMO2 fusion) showed the highest sensitivity compared to ALL-SIL (harbors ABL class fusion) and other T-ALL cell lines. For each leukemia sample at each drug concentration, cells were tested in duplicates.
